Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.32 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726911 | 0.92 | — | — | |
| SCHEMBL3477097 | 0.82 | ALDH1A1 (0.43) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL6725195 | 0.80 | — | — | |
| SCHEMBL6724770 | 0.77 | APP (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL34468810 | 0.77 | CYP1A2 (0.38) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL9365663 | 0.75 | CYP2C19 (0.46) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL9256535 | 0.75 | CYP2C19 (0.46) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL9253225 | 0.75 | CYP2C19 (0.46) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL30934054 | 0.75 | CYP2C19 (0.46) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL9366283 | 0.75 | CYP2C19 (0.46) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6150303-A | Substituted 3-phenylisoxazolines | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-21 | — | — | US | disclosed |
| CN-1189824-A | 1-amino-3-benzyluracils | BASF AG (DE) | 1998-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | CYP1A2 32/4885CYP2D6 354/4885MAPT 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.